| 0 (0%) | 09-16 07:36 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 51.2  |
1-year : | 54.61 |
| Resists | First : | 43.84 |
Second : | 46.75 |
| Pivot price | 43.07 |
|||
| Supports | First : | 39.11 |
Second : | 32.54 |
| MAs | MA(5) : | 41.62 |
MA(20) : | 42.73 |
| MA(100) : | 47.13  |
MA(250) : | 41.51 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 16.5 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 60.9 | Low : | 29.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VCYT ] has closed above bottom band by 0.1%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.41 - 42.62 | 42.62 - 42.82 |
| Low: | 38.54 - 38.79 | 38.79 - 39.03 |
| Close: | 39.68 - 40.07 | 40.07 - 40.46 |
Tue, 15 Sep 2026
VCYT: Acquisition and innovation drive portfolio growth, with strong test performance and expanding market reach - TradingView
Tue, 15 Sep 2026
VCYT: Acquisition-driven expansion, strong test growth, and robust evidence fuel portfolio and market leadership - TradingView
Mon, 14 Sep 2026
VCYT Looks 5.7% Overvalued on GF Value™ as Insider Selling Persi - GuruFocus
Mon, 14 Sep 2026
VCYT Looks 5.7% Overvalued on GF Value™ After Convergent Genomics Acquisition - GuruFocus
Mon, 14 Sep 2026
After bladder treatment, a urine test split patients: 25% vs. 91% stayed recurrence-free - Stock Titan
Thu, 10 Sep 2026
Veracyte (VCYT) Gets a Buy from UBS - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 80 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 113.4 (%) |
| Shares Short | 6,790 (K) |
| Shares Short P.Month | 6,670 (K) |
| EPS | 1.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.28 |
| Profit Margin | 20.3 % |
| Operating Margin | 15.2 % |
| Return on Assets (ttm) | 4 % |
| Return on Equity (ttm) | 8.7 % |
| Qtrly Rev. Growth | 15.5 % |
| Gross Profit (p.s.) | 5.15 |
| Sales Per Share | 6.98 |
| EBITDA (p.s.) | 1.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 178 (M) |
| Levered Free Cash Flow | 106 (M) |
| PE Ratio | 28.67 |
| PEG Ratio | 0 |
| Price to Book value | 2.32 |
| Price to Sales | 5.74 |
| Price to Cash Flow | 18.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|